During Tuesday’s Current trade, Shares of 3D Systems Corporation (NYSE:DDD), lost -3.64% to $13.23.
3D Systems (DDD) declared that it has expanded its PlasticJet Printing materials to comprise a new Nylon for the company’s flagship CubePro(R) 3D printers. This engineering-grade performance material was developed for CubePro , bringing strength, flexibility and unparalleled durability to desktop production of functional parts for design, testing and small-scale manufacturing. Engineered with a blend that comprises Nylon 6 and compatible with InfinityTM Rinse-Away water-soluble support material, Nylon for CubePro saves valuable design and process time and enables 3D printing of complex, articulated and fully assembled end-use parts.
Nylon for Cube Pro is delivered in a new Smart Cartridge that is equipped with a hydroscopic seal extending the material’s shelf life for up to 12 months. Nylon cartridges are priced at $149 each, and are accessible right away on Cubify and through select distributors. Combining Nylon with InfinityTM Rinse-Away support inside the CubePro’s climate controlled chamber delivers the highest quality professional desktop 3D printing output every time.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries. The company’s 3D printers transform data input from the format generated by 3D design software, CAD software, or 3D scanning and sculpting devices to printed parts using integrated, engineered plastic, metal, nylon, rubber, wax, and composite print materials. It offers stereolithography, selective laser sintering, direct metal, multi-jet, color jet, and film transfer imaging printers, in addition to plastic jet printing 3D printers.
Shares of Hilton Worldwide Holdings Inc (NYSE:HLT), declined -1.69% to $24.42, during its current trading session.
A New England hotel rich in history, Madison Beach Hotel, recently joined Curio – A Collection by Hilton, Hilton Worldwide’s growing global collection of distinctive hotels for passionate travelers seeking local discovery and authentic experiences. Set in a relaxing beachfront setting, Madison Beach Hotel is an upscale boutique resort with each of the hotel’s 32 rooms offering luxurious accommodations with sweeping ocean views and private balconies. Located in the heart of Madison Beach, the hotel is the area’s only resort on the beach and is ideally situated near a variety of dining, recreation and shopping areas.
Madison Beach Hotel’s rich history dates back to the early 1900s when it originally served as a rooming house for shipbuilders passing through the region. The hotel has also welcomed thousands of train passengers over the years, attracted by the natural beauty of Madison’s beaches. The hotel was one of the oldest continuously run businesses on the shoreline of Connecticut. In 2012, the hotel was completely rebuilt and re-opened to the public.
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations. As of June 2, 2015, it had about 4,350 managed, franchised, owned, and leased hotels and timeshare properties with about 720,000 rooms in 94 countries and territories.
BB&T Corporation (NYSE:BBT), during its Tuesday’s current trading session decreased -3.02% to $35.80.
BB&T (BBT) declared it has accomplished its acquisition of The Bank of Kentucky Financial Corporation. Systems were converted during the weekend and branches in northern Kentucky and Cincinnati opened recently under the BB&T name.
The acquisition, which was declared in September 2014, comprises 32 retail branches in northern Kentucky and Cincinnati. The merger comprises $1.6 billion in deposits, $1.3 billion in loans and total assets of $1.9 billion based on March 31, 2015, balances. BB&T received the required regulatory approvals for the acquisition earlier this year.
BB&T Corporation operates as a financial holding company that provides various banking and trust services for retail and commercial clients. It operates in six segments: Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Services, and Financial Services. The company’s deposit products comprise noninterest-bearing checking accounts, interest-bearing checking accounts, savings accounts, money market deposit accounts, certificates of deposit, and individual retirement accounts.
Finally, Novavax, Inc. (NASDAQ:NVAX), decreased -3.16%, to $10.44.
Novavax, Inc. (NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared positive top-line data from a Phase 2 clinical trial of its recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate (Seasonal Influenza VLP). This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Department of Health and Human Services under the Company’s contract with HHS-BARDA (HHSO100201100012C). The trial demonstrated that the Seasonal Influenza VLP vaccine candidate was well-tolerated with no vaccine-related serious adverse events. The trial met its immunogenicity targets and demonstrated potential to meet the Center for Biological Evaluation and Research (CBER) criteria for accelerated approval.
Novavax’ technology platform enables the creation of recombinant, strain-specific VLPs. Novavax’ Seasonal Influenza VLP comprises of VLPs representing four different strains of influenza virus, each expressing strain-specific hemagglutinin and neuraminidase antigens. This dose-ranging clinical trial was designed to evaluate the safety and immunogenicity of the Seasonal Influenza VLP in 400 healthy adults. The primary outcomes of the trial assessed safety and tolerability of the Seasonal Influenza VLP and quantified immune responses to each of the four influenza strains based on hemagglutination-inhibiting antibody titers. The secondary outcomes evaluated neuraminidase-inhibiting antibody titers for all four influenza strains.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline comprises respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, in addition to pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, in addition to rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
